QQQ   420.80 (+1.48%)
AAPL   166.97 (+1.19%)
MSFT   402.45 (+0.83%)
META   487.90 (+1.42%)
GOOGL   157.52 (+2.23%)
AMZN   178.02 (+1.94%)
TSLA   141.91 (-3.50%)
NVDA   797.40 (+4.65%)
AMD   149.19 (+1.74%)
NIO   4.03 (+6.05%)
BABA   70.71 (+2.37%)
T   16.33 (-1.09%)
F   12.88 (+6.10%)
MU   109.78 (+2.82%)
GE   151.43 (+2.28%)
CGC   8.00 (+0.88%)
DIS   113.23 (+0.55%)
AMC   3.38 (+6.96%)
PFE   26.44 (+1.69%)
PYPL   63.62 (+2.10%)
XOM   121.53 (+1.38%)
QQQ   420.80 (+1.48%)
AAPL   166.97 (+1.19%)
MSFT   402.45 (+0.83%)
META   487.90 (+1.42%)
GOOGL   157.52 (+2.23%)
AMZN   178.02 (+1.94%)
TSLA   141.91 (-3.50%)
NVDA   797.40 (+4.65%)
AMD   149.19 (+1.74%)
NIO   4.03 (+6.05%)
BABA   70.71 (+2.37%)
T   16.33 (-1.09%)
F   12.88 (+6.10%)
MU   109.78 (+2.82%)
GE   151.43 (+2.28%)
CGC   8.00 (+0.88%)
DIS   113.23 (+0.55%)
AMC   3.38 (+6.96%)
PFE   26.44 (+1.69%)
PYPL   63.62 (+2.10%)
XOM   121.53 (+1.38%)
QQQ   420.80 (+1.48%)
AAPL   166.97 (+1.19%)
MSFT   402.45 (+0.83%)
META   487.90 (+1.42%)
GOOGL   157.52 (+2.23%)
AMZN   178.02 (+1.94%)
TSLA   141.91 (-3.50%)
NVDA   797.40 (+4.65%)
AMD   149.19 (+1.74%)
NIO   4.03 (+6.05%)
BABA   70.71 (+2.37%)
T   16.33 (-1.09%)
F   12.88 (+6.10%)
MU   109.78 (+2.82%)
GE   151.43 (+2.28%)
CGC   8.00 (+0.88%)
DIS   113.23 (+0.55%)
AMC   3.38 (+6.96%)
PFE   26.44 (+1.69%)
PYPL   63.62 (+2.10%)
XOM   121.53 (+1.38%)
QQQ   420.80 (+1.48%)
AAPL   166.97 (+1.19%)
MSFT   402.45 (+0.83%)
META   487.90 (+1.42%)
GOOGL   157.52 (+2.23%)
AMZN   178.02 (+1.94%)
TSLA   141.91 (-3.50%)
NVDA   797.40 (+4.65%)
AMD   149.19 (+1.74%)
NIO   4.03 (+6.05%)
BABA   70.71 (+2.37%)
T   16.33 (-1.09%)
F   12.88 (+6.10%)
MU   109.78 (+2.82%)
GE   151.43 (+2.28%)
CGC   8.00 (+0.88%)
DIS   113.23 (+0.55%)
AMC   3.38 (+6.96%)
PFE   26.44 (+1.69%)
PYPL   63.62 (+2.10%)
XOM   121.53 (+1.38%)

Arvinas (ARVN) Competitors

$35.64
+0.92 (+2.65%)
(As of 02:34 PM ET)

ARVN vs. DYN, SNDX, MORF, AKRO, PRTA, PLRX, ARCT, ANNX, ENTA, and RVMD

Should you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Dyne Therapeutics (DYN), Syndax Pharmaceuticals (SNDX), Morphic (MORF), Akero Therapeutics (AKRO), Prothena (PRTA), Pliant Therapeutics (PLRX), Arcturus Therapeutics (ARCT), Annexon (ANNX), Enanta Pharmaceuticals (ENTA), and Revolution Medicines (RVMD). These companies are all part of the "medical" sector.

Arvinas vs.

Dyne Therapeutics (NASDAQ:DYN) and Arvinas (NASDAQ:ARVN) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, community ranking, media sentiment, risk, profitability, analyst recommendations and dividends.

Arvinas received 156 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. Likewise, 64.73% of users gave Arvinas an outperform vote while only 64.71% of users gave Dyne Therapeutics an outperform vote.

CompanyUnderperformOutperform
Dyne TherapeuticsOutperform Votes
11
64.71%
Underperform Votes
6
35.29%
ArvinasOutperform Votes
167
64.73%
Underperform Votes
91
35.27%

Dyne Therapeutics has a net margin of 0.00% compared to Dyne Therapeutics' net margin of -185.09%. Dyne Therapeutics' return on equity of -70.24% beat Arvinas' return on equity.

Company Net Margins Return on Equity Return on Assets
Dyne TherapeuticsN/A -136.35% -103.67%
Arvinas -185.09%-70.24%-31.79%

Dyne Therapeutics presently has a consensus target price of $37.43, indicating a potential upside of 55.69%. Arvinas has a consensus target price of $59.73, indicating a potential upside of 69.02%. Given Dyne Therapeutics' higher possible upside, analysts clearly believe Arvinas is more favorable than Dyne Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyne Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14
Arvinas
0 Sell rating(s)
2 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.88

In the previous week, Arvinas had 4 more articles in the media than Dyne Therapeutics. MarketBeat recorded 6 mentions for Arvinas and 2 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.22 beat Arvinas' score of 0.96 indicating that Arvinas is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dyne Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Arvinas
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 20.8% of Dyne Therapeutics shares are held by insiders. Comparatively, 5.2% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Dyne Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500.

Dyne Therapeutics has higher earnings, but lower revenue than Arvinas. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyne TherapeuticsN/AN/A-$235.94M-$3.94-6.25
Arvinas$78.50M30.79-$367.30M-$6.50-5.44

Summary

Arvinas beats Dyne Therapeutics on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARVN vs. The Competition

MetricArvinasPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.42B$6.27B$4.64B$7.31B
Dividend YieldN/A3.10%5.46%3.98%
P/E Ratio-5.447.92181.0616.24
Price / Sales30.79302.982,596.1880.96
Price / CashN/A19.0131.1927.20
Price / Book2.955.594.594.45
Net Income-$367.30M$136.96M$99.84M$212.71M
7 Day Performance1.90%-0.53%108.82%-0.25%
1 Month Performance-15.56%-6.92%106.69%-1.31%
1 Year Performance23.97%1.55%132.80%5.49%

Arvinas Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DYN
Dyne Therapeutics
3.3593 of 5 stars
$27.23
+1.2%
$37.43
+37.5%
+110.2%$2.23BN/A-6.91141Positive News
SNDX
Syndax Pharmaceuticals
2.9183 of 5 stars
$23.00
+0.8%
$34.42
+49.6%
-3.3%$1.95B$139.71M-7.77184
MORF
Morphic
3.7004 of 5 stars
$30.77
+2.3%
$61.00
+98.2%
-37.6%$1.54B$520,000.00-8.82121Upcoming Earnings
AKRO
Akero Therapeutics
3.4807 of 5 stars
$23.74
+2.6%
$39.00
+64.3%
-55.2%$1.34BN/A-8.3355Analyst Report
PRTA
Prothena
3.1331 of 5 stars
$23.54
-0.6%
$69.63
+195.8%
-61.2%$1.27B$91.37M-8.41173
PLRX
Pliant Therapeutics
3.1427 of 5 stars
$14.92
+1.4%
$48.44
+224.7%
-58.7%$898.78M$1.58M-5.35158
ARCT
Arcturus Therapeutics
1.6766 of 5 stars
$31.66
+2.4%
$61.33
+93.7%
-6.1%$832.48M$157.75M-30.44180
ANNX
Annexon
3.293 of 5 stars
$6.23
+3.0%
$14.43
+131.6%
-18.7%$560.89MN/A-3.5076Gap Down
ENTA
Enanta Pharmaceuticals
3.7025 of 5 stars
$16.82
+2.8%
$19.33
+14.9%
-63.8%$355.91M$79.20M-2.56145Positive News
RVMD
Revolution Medicines
4.3432 of 5 stars
$32.99
+3.4%
$38.80
+17.6%
+43.8%$5.43B$11.58M-8.75378

Related Companies and Tools

This page (NASDAQ:ARVN) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners